• Home
  • » 
  • Reports
  • » 
  • Generics Market: Focus on Value-Added Me...

Generics Market

Generics Market: Focus on Value-Added Medicines / Supergenerics, 2019-2030

  • Lowest Price Guaranteed From USD 4,499

  • Published
    October 2019

  • Pages
    231

  • View Count
    6433

  • Buy Now

Example Insights

This image highlights the context of Generics Market report. Given lucrative cost benefits and marketing exclusivity, supergeneric medicines represent an attractive product segment within the modern pharma industry; upcoming patent expiries of blockbuster drugs have intensified the interest in this field This image provides list of Approved Value-Added Medicines / Supergenerics. Over time, there has been a significant increase in interest in value added generic drugs; in fact, in the last three years alone, more than 130 such products have been approved for the treatment of various diseases This image provides list of Available Technologies for Value Added Drug Development. Currently, there are several technology platforms, capable of significantly enhancing the properties of existing therapeutic products and / or improving therapy adherence, available for use by supergeneric drug developers
This image presents current market landscape of Supergeneric Development Technologies. The primary focus in this domain is on improving small-molecule drugs and conferring controlled-release properties to oral formulations of such products This image highlights the geographical distribution of Supergeneric Development Technologies. Upcoming technologies are increasingly exploiting parenteral routes of drug delivery; the US is currently considered to be the base of operations for majority of such companies This image highlights competitive analysis of Supergeneric Development Technologies. In order to achieve an edge over competing players, technology developers in this market are increasingly focusing on the integration of advanced features in their respective platforms and affiliated offerings
This image provides list of Likely Drug Candidates for Supergeneric Development. An evaluation of close to 150 generic drugs marketed over last three years revealed several drugs / product candidates that are likely to be reformulated as value-added medicines in the near future This image provides information on the current and future market trends and potential growth of Value-Added Medicines Market. Driven by expansion into diverse therapeutic areas and exploitation of different routes of delivery, the long term opportunity in this market is likely to evolve at an annualized rate of ~17%  

Report Description

Generics Market Overview

In 2018, it was estimated that the availability of low-cost, generic versions of pharmaceutical interventions saved nearly USD 1.6 trillion in healthcare costs in the US over the last decade.  Given the cost benefits offered, generic medicines usually have high adoption rates. Moreover, upcoming patent expiries of several blockbuster drugs, such as LYRICA®, Cialis®, Advair® and Sensipar®, have intensified the interest of several drug manufacturers in the development of generics. As more generic drugs get approved by regulators across the globe, the competition in the industry has steadily increased. Interestingly, in 2018, the US FDA approved more than 780 generic products, which represented more than 90% increase in the number of such drug approvals since 2014.  The most evident impact of the growth in competition in this domain is deflation of cost of generics, resulting in diminished profit margins for the developers of such products. Therefore, to ensure sustainable growth within the off-patent drug products market, companies are gradually adopting innovative drug alteration techniques in order to develop value added medicinal products, which offer better commercial benefits. 

The availability of several advanced drug development and technology platforms have enabled the fabrication and formulation of improved versions of existing drug products. Such modified pharmacological interventions are commonly referred to as supergenerics / complex generics / value-added generics. Although supergenerics are based on the same mechanism of action as that of the original drug, these versions usually have certain additional attributes, such as a new active ingredient, improved manufacturing process, alternative dosage regimen, modified release properties or different formulation. Typically, such drugs are granted a form of marketing exclusivity (for a period of 3-7 years ), enabling their developers to generate relatively higher profit margins, compared to conventional generics. Moreover, the development of value added generics is generally directed at certain unmet clinical needs, which may have been unaddressed by previous versions of the drug. In addition, the approval process for such products is not as complicated; in the US, value added medicines are evaluated under the FDA’s 505(b)(2) pathway. This evolving segment of the pharmaceutical industry has also witnessed a surge in the availability of technology providers, offering a diverse range of platforms / solutions to support the development of supergeneric drugs. After a detailed analysis of prevalent trends, we are led to believe that value-added generic products market is poised to witness significant growth over the coming years.

Scope of the Reports

The ‘Generics Market: Focus on Value-added Medicines / Supergenerics, 2019-2030’ report features an extensive study of supergenerics, as well as the current landscape and future potential of technology providers that are offering innovative platforms / solutions to supergeneric drug developers. Amongst other elements, the report features:

  • An overview of recently approved supergenerics (over the period 2016-2018), featuring information on route of administration, target disease indication(s), target therapeutic area(s), approval timeline, submission classification code and most active drug developers (in terms of number of product approvals). Additionally, it provides a detailed assessment of technology providers, offering platforms / solutions for supergeneric drug development, including information on year of establishment, company size and geographical location.
  • An informed competitiveness analysis of the technologies captured in our database, taking into consideration relevant parameters, such as supplier power (based on company size of technology provider) and other important technology-related specifications, such as the type of molecule, impact on drug properties and route of administration.
  • Elaborate profiles of prominent technology developers engaged in this domain, featuring an overview of the company, its financial information (if available), a detailed description of its technology platform(s), recent developments and a comprehensive future outlook.
  • A list of marketed generics that, we believe, are likely to be developed as supergenerics in the near future, based on an in-depth analysis taking into consideration multiple relevant parameters, such as the current annual cost of treatment of the parent drug, year of patent expiry, revenues generated in the year before patent expiry, target therapeutic area and number of competitor (generic) drugs available in the market.
  • Detailed case studies on five approved supergeneric drugs, including an overview of the product along with information on the original / parent drug, value proposition offered by the supergeneric version, pricing strategies adopted by the developer (if available), annual revenues of the supergeneric and parent drug (if available) and the key learnings / takeaways from individual case studies.
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall supergenerics industry.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as size of the generic drugs market, share of supergenerics within the generic drugs market and expected annual growth rate across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2019-2030. The chapter also presents a detailed market segmentation across [A] different therapeutic areas (autoimmune disorders, cardiovascular disorders, CNS disorders, metabolic disorders, oncological disorders, pain disorders, respiratory disorders and others), [B] routes of administration (parenteral, intravitreal, oral, topical and others) and [C] key geographical regions (North America, Asia-Pacific, Europe, South America, and Africa and Middle East).

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outline

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the supergeneric drugs market in the mid to long term.

Chapter 3 provides an overview of generic drugs and the contemporary challenges related to such products, such as price erosion, growing competition and unfavorable policy changes by regulatory authorities. It further highlights the rise of supergenerics / value added generics and the various techniques used for the development of these products. The chapter also provides a brief outline of the regulatory pathways involved in the approval process of supergeneric drugs. Further, it includes a discussion on the various advantages and limitations / constraints within this evolving segment of the pharmaceutical industry.

Chapter 4 provides an overview of recently approved supergenerics (over the period 2016-2018). The chapter presents detailed analyses of these drugs based on several relevant parameters, such as route of administration, target disease indication(s), target therapeutic area(s), approval timeline, submission classification code and most active drug developers (in terms of number of product approvals). 

Chapter 5 provides an overview of industry players that are actively engaged in offering technology platforms for the development of supergenerics. The chapter presents an analysis of these players on the basis of their year of establishment, geographical location and company size. It also provides a list of the various technologies offered by the aforementioned companies, along with a detailed competitiveness analysis based on parameters, such as compatibility with different types of molecules, routes of administration, and impact on drug properties.

Chapter 6 includes detailed profiles of prominent technology developers engaged in this domain, featuring an overview of the company, its financial information (if available), a detailed description of its technology platform(s), recent developments and a comprehensive future outlook.

Chapter 7 presents detailed case studies on five approved supergeneric drugs, including an overview of the product along with information on the original / parent drug, value proposition offered by the supergeneric version, pricing strategies adopted by the developer (if available), annual revenues of the supergeneric and parent drug (if available) and the key learnings / takeaways from individual case studies.

Chapter 8  provides a list of marketed generics that are likely to be developed as supergenerics in the near future, based on a detailed analysis of potential candidates, taking into consideration various parameters, including the current annual cost of treatment of parent drug, its year of patent expiry, revenues generated by the parent drug in the year before patent expiry, target therapeutic area and number of competitor generic drugs available in the market.

Chapter 9 provides a discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall supergeneric drugs industry.

Chapter 10 presents a detailed market forecast, highlighting the future potential of the supergenerics market till the year 2030. The chapter features the likely distribution of the opportunity across different [A] type of therapeutic areas (autoimmune disorders, cardiovascular disorders, CNS disorders, metabolic disorders, oncological disorders, pain disorders, respiratory disorders and others), [B] routes of administration (parenteral, intravitreal, oral, topical and others) and [C] geographical regions (North America, Asia-Pacific, Europe, South America, and Africa and Middle East).

Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 13 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3 INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Generic Drugs
3.2.1. Key Challenges within the Generics Industry
3.2.1.1. Policy Changes
3.2.1.2. Increasing Competition
3.2.1.3. Price Erosion

3.3. Supergenerics
3.3.1. Techniques Used for the Development of Supergenerics
3.3.2. Regulatory Pathways for Approval of Supergenerics

3.4. Advantages of Supergenerics
3.4.1. Improved Efficacy
3.4.2. Increased IP Protection
3.4.3. Cost and Time Efficient Development Process

3.5. Challenges Related to Supergenerics
3.6. Future Perspectives

4 SUPERGENERIC DRUGS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Supergenerics: Overall Market Overview
4.2.1. Analysis by Route of Administration
4.2.2. Analysis by Target Indication
4.2.3. Analysis by Target Therapeutic Area
4.2.4. Analysis by Approval Timeline
4.2.5. Analysis by Submission Classification Code
4.2.6. Analysis by Route of Administration, Target Therapeutic Area and Submission Classification Code
4.2.7. Analysis by Most Active Players

5 TECHNOLOGY PROVIDERS FOR SUPERGENERIC DEVELOPMENT: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Supergenerics Technology Providers: Overall Market Overview
5.3. Analysis by Type of Drug Modification
5.4. Analysis by Type of Technology
5.5. Analysis by Type of Molecules Formulated / Delivered
5.6. Analysis by Route of Administration
5.7. Analysis by Type of Value Addition
5.8. Analysis by Type of Molecule, Route of Administration and Type of Value Addition
5.9. Analysis by Year of Establishment
5.10. Analysis by Company Size
5.11. Analysis by Geography
5.12 Platform Competitiveness Analysis
5.12.1 Competitiveness Analysis: Technologies of Companies Based in North America
5.12.2 Competitiveness Analysis: Technologies of Companies Based in Europe
5.12.3 Competitiveness Analysis: Technologies of Companies Based in Asia-Pacific

6 COMPANY PROFILES: SUPERGENERIC TECHNOLOGY PROVIDERS
6.1. Chapter Overview
6.2. Ascendia Pharmaceuticals
6.2.1. Company Overview
6.2.2. Technology Overview
6.2.2.1. NanoSol
6.2.2.2. AmorSol
6.2.2.3. EmulSol
6.2.3. Recent Developments and Future Outlook

6.3. CritiTech
6.3.1. Company Overview
6.3.2. Technology Overview
6.3.2.1. Spray Drying Technology
6.3.2.2. Supercritical Precipitation Technology
6.3.3. Recent Developments and Future Outlook

6.4. Crossject
6.4.1. Company Overview
6.4.2. Technology Overview
6.4.2.1. ZENEO®
6.4.3. Recent Developments and Future Outlook

6.5. DelSiTech
6.5.1. Company Overview
6.5.2. Technology Overview
6.5.2.1. DelSiTech™ Silica
6.5.3. Recent Developments and Future Outlook

6.6. Heron Therapeutics
6.6.1. Company Overview
6.6.2. Technology Overview
6.6.2.1. Biochronomer®
6.6.3. Recent Developments and Future Outlook

6.7. Intellipharmaceutics International
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Technology Overview
6.7.3.1. Hypermatrix™
6.7.3.2. nPODDDS™
6.7.3.3. PODRAS™
6.7.3.4. IntelliFOAM™
6.7.3.5. IntelliGITransporter™
6.7.3.6. IntelliMatrix™
6.7.3.7. IntelliOsmotics™
6.7.3.8. IntelliPaste™
6.7.3.9. IntelliPellets™
6.7.3.10. IntelliShuttle™
6.7.4. Recent Developments and Future Outlook

6.8. Kashiv BioSciences
6.8.1. Company Overview
6.8.2. Technology Overview
6.8.2.1. GRANDE™
6.8.2.2. KRONOTEC™
6.8.2.3. BIOMAXX®
6.8.2.4. LOAD®
6.8.3. Recent Developments and Future Outlook

6.9. Latitude Pharmaceuticals
6.9.1. Company Overview
6.9.2. Technology Overview
6.9.2.1. Nano-E™
6.9.2.2. PG-Depot™
6.9.2.3. ARTSS™
6.9.2.4. RFAP™ Matrix
6.9.2.5. RTTS
6.9.2.6. 24H™
6.9.2.7. MiniSpheres
6.9.2.8. GelPatch
6.9.3. Recent Developments and Future Outlook

6.10. Mayne Pharma
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Technology Overview
6.10.3.1. SUBA™
6.10.3.2. Cleantaste™
6.10.3.3. Pellet Technology
6.10.4. Recent Developments and Future Outlooks

6.11. Neurelis
6.11.1. Company Overview
6.11.2. Technology Overview
6.11.2.1. Intravail®
6.11.2.2. ProTek®
6.11.2.3. Hydrogel™
6.11.3. Recent Developments and Future Outlook

6.12. Rubicon Research
6.12.1. Company Overview
6.12.2. Technology Overview
6.12.2.1. RubiERT®
6.12.2.2. RubiDT®
6.12.2.3. RubiReten®
6.12.2.4. RubiSRL®
6.12.3. Recent Developments and Future Outlook

6.13. Taiwan Liposome Company
6.13.1. Company Overview
6.13.2. Financial Information
6.13.3. Technology Overview
6.13.3.1. BioSeizer®
6.13.3.2. NanoX™
6.13.3.3. Polymeric Micelle
6.13.4. Recent Developments and Future Outlook

6.14. tesa Labtec
6.14.1. Company Overview
6.14.2. Technology Overview
6.14.2.1. Transfilm®
6.14.2.2. Mucofilm®
6.14.2.3. Rapidfilm®
6.14.3. Recent Developments and Future Outlook

7 CASE STUDY OF APPROVED SUPERGENERIC DRUGS
7.1. Chapter Overview
7.2. Austedo®
7.2.1. Overview
7.2.2. Originator Drug Overview
7.2.3. Value Proposition
7.2.4. Financial Information
7.2.5. Key Learnings

7.3. Abraxane®
7.3.1. Overview
7.3.2. Originator Drug Overview
7.3.3. Value Proposition
7.3.4. Financial Information
7.3.5. Key Learnings

7.4. Avycaz®
7.4.1. Overview
7.4.2. Originator Drug Overview
7.4.3. Value Proposition
7.4.4. Financial Information
7.4.5. Key Learnings

7.5. Procysbi®
7.5.1. Overview
7.5.2. Originator Drug Overview
7.5.3. Value Proposition
7.5.4. Financial Information
7.5.5. Key Learnings

7.6. Trokendi XR®
7.6.1. Overview
7.6.2. Originator Drug Overview
7.6.3. Value Proposition
7.6.4. Financial Information
7.6.5. Key Learnings

8 LIKELY DRUG CANDIDATES FOR SUPERGENERIC DEVELOPMENT
8.1. Chapter Overview
8.2. Marketed Generic Drugs, 2016-2018
8.2.1. Most Likely Candidates for supergeneric development
8.2.2. Likely Candidates for supergeneric development
8.2.3. Less Likely Candidates for supergeneric development
8.2.4. Least Likely Candidates for supergeneric development

9 SWOT ANALYSIS
9.1. Chapter Overview
9.2. Strengths
9.3. Weakness
9.4. Opportunities
9.5. Threats
9.6. Concluding Remarks

10 MARKET FORECAST
10.1. Chapter Overview
10.2. Overall Supergeneric Drugs Market, 2019-2030
10.3. Supergeneric Drugs Market: Distribution by Therapeutic Area, 2019-2030
10.4. Supergeneric Drugs Market: Distribution by Route of Administration, 2019- 2030
10.5. Supergeneric Drugs Market: Distribution by Geography, 2019-2030

10.5.1. Supergeneric Drugs Market in North America, 2019-2030

10.5.1.1. Supergeneric Drugs Market in North America: Distribution by Therapeutic Area,2019-2030

10.5.1.1.1. Supergeneric Drugs Market for CNS Disorders in North America, 2019-2030
10.5.1.1.2. Supergeneric Drugs Market for Cardiovascular Disorders in North America, 2019 and 2030
10.5.1.1.3. Supergeneric Drugs Market for Respiratory Disorders in North America, 2019 and 2030
10.5.1.1.4. Supergeneric Drugs Market for Autoimmune Disorders in North America, 2019 and 2030
10.5.1.1.5. Supergeneric Drugs Market for Metabolic Disorders in North America, 2019 and 2030
10.5.1.1.6. Supergeneric Drugs Market for Oncological Disorders in North America, 2019 and 2030
10.5.1.1.7. Supergeneric Drugs Market for Pain Disorders in North America, 2019 and 2030
10.5.1.1.8. Supergeneric Drugs Market for Other Disorders in North America, 2019 and 2030

10.5.1.2. Supergeneric Drugs Market Distribution by Route of Administration in North
10.5.1.2.1. Supergeneric Drugs Market for Oral Route of Administration in North America, 2019-2050
10.5.1.2.2. Supergeneric Drugs Market for Parenteral Route of Administration in North America, 2019 and 2030
10.5.1.2.3. Supergeneric Drugs Market for Topical Route of Administration in North America, 2019 and 2030
10.5.1.2.4. Supergeneric Drugs Market for Intravitreal Route of Administration in North America, 2019 and 2030
10.5.1.2.5. Supergeneric Drugs Market for Other Routes of Administration in North America, 2019 and 2030

10.5.2. Supergeneric Drugs Market in Europe, 2019-2030
10.5.2.1. Supergeneric Drugs Market: Distribution by Therapeutic Area in Europe
10.5.2.1.1. Supergeneric Drugs Market for CNS Disorders in Europe, 2019 and 2030
10.5.2.1.2. Supergeneric Drugs Market for Cardiovascular Disorders in Europe, 2019 and 2030
10.5.2.1.3. Supergeneric Drugs Market for Respiratory Disorders in Europe, 2019 and 2030
10.5.2.1.4. Supergeneric Drugs Market for Autoimmune Disorders in Europe, 2019 and 2030
10.5.2.1.5. Supergeneric Drugs Market for Metabolic Disorders in Europe, 2019 and 2030
10.5.2.1.6. Supergeneric Drugs Market for Oncological Disorders in Europe, 2019 and 2030
10.5.2.1.7. Supergeneric Drugs Market for Pain Disorders in Europe, 2019 and 2030
10.5.2.1.8. Supergeneric Drugs Market for Other Disorders in Europe, 2019 and 2030
10.5.2.2. Supergeneric Drugs Market Distribution by Route of Administration in Europe
10.5.2.2.1. Supergeneric Drugs Market for Oral Route of Administration in Europe, 2019 and 2030
10.5.2.2.2. Supergeneric Drugs Market for Parenteral Route of Administration in Europe, 2019 and 2030
10.5.2.2.3. Supergeneric Drugs Market for Topical Route of Administration in Europe, 2019 and 2030
10.5.2.2.4. Supergeneric Drugs Market for Intravitreal Route of Administration in Europe, 2019 and 2030
10.5.2.2.5. Supergeneric Drugs Market for Other Routes of Administration in Europe, 2019 and 2030

10.5.3. Supergeneric Drugs Market in Asia-Pacific, 2019-2030
10.5.3.1. Supergeneric Drugs Market: Distribution by Therapeutic Area in Asia-Pacific
10.5.3.1.1. Supergeneric Drugs Market for CNS Disorders in Asia-Pacific, 2019 and 2030
10.5.3.1.2. Supergeneric Drugs Market for Cardiovascular Disorders in Asia-Pacific, 2019 and 2030
10.5.3.1.3. Supergeneric Drugs Market for Respiratory Disorders in Asia-Pacific, 2019 and 2030
10.5.3.1.4. Supergeneric Drugs Market for Autoimmune Disorders in Asia-Pacific, 2019 and 2030
10.5.3.1.5. Supergeneric Drugs Market for Metabolic Disorders in Asia-Pacific, 2019 and 2030
10.5.3.1.6. Supergeneric Drugs Market for Oncological Disorders in Asia-Pacific, 2019 and 2030
10.5.3.1.7. Supergeneric Drugs Market for Pain Disorders in Asia-Pacific, 2019 and 2030
10.5.3.1.8. Supergeneric Drugs Market for Other Disorders in Asia-Pacific, 2019 and 2030
10.5.3.2. Supergeneric Drugs Market Distribution by Route of Administration in Asia-Pacific
10.5.3.2.1. Supergeneric Drugs Market for Oral Route of Administration in Asia-Pacific,2019 and 2030

10.5.3.2.2. Supergeneric Drugs Market for Parenteral Route of Administration in Asia-Pacific, 2019 and 2030
10.5.3.2.3. Supergeneric Drugs Market for Topical Route of Administration in Asia-Pacific, 2019 and 2030
10.5.3.2.4. Supergeneric Drugs Market for Intravitreal Route of Administration in Asia-Pacific, 2019 and 2030
10.5.3.2.5. Supergeneric Drugs Market for Other Routes of Administration in Asia-Pacific, 2019 and 2030

10.5.4. Supergeneric Drugs Market in Latin America, 2019-2030
10.5.4.1. Supergeneric Drugs Market: Distribution by Therapeutic Area in Latin America
10.5.4.1.1. Supergeneric Drugs Market for CNS Disorders in Latin America, 2019 and 2030
10.5.4.1.2. Supergeneric Drugs Market for Cardiovascular Disorders in Latin America, 2019 and 2030
10.5.4.1.3. Supergeneric Drugs Market for Respiratory Disorders in Latin America, 2019 and 2030
10.5.4.1.4. Supergeneric Drugs Market for Autoimmune Disorders in Latin America, 2019 and 2030
10.5.4.1.5. Supergeneric Drugs Market for Metabolic Disorders in Latin America, 2019 and 2030
10.5.4.1.6. Supergeneric Drugs Market for Oncological Disorders in Latin America, 2019 and 2030
10.5.4.1.7. Supergeneric Drugs Market for Pain Disorders in Latin America, 2019 and 2030
10.5.4.1.8. Supergeneric Drugs Market for Other Disorders in Latin America, 2019 and 2030
10.5.4.2. Supergeneric Drugs Market Distribution by Route of Administration in Latin America
10.5.4.2.1. Supergeneric Drugs Market for Oral Route of Administration in Latin America, 2019 and 2030
10.5.4.2.2. Supergeneric Drugs Market for Parenteral Route of Administration in Latin America, 2019 and 2030
10.5.4.2.3. Supergeneric Drugs Market for Topical Route of Administration in Latin America, 2019 and 2030
10.5.4.2.4. Supergeneric Drugs Market for Intravitreal Route of Administration in Latin America, 2019 and 2030
10.5.4.2.5. Supergeneric Drugs Market for Other Routes of Administration in Latin America, 2019 and 2030

10.5.5. Supergeneric Drugs Market in Africa and Middle-East, 2019-2030
10.5.5.1. Supergeneric Drugs Market: Distribution by Therapeutic Area in Africa and Middle East
10.5.5.1.1. Supergeneric Drugs Market for CNS Disorders in Africa and Middle-East, 2019 and 2030
10.5.5.1.2. Supergeneric Drugs Market for Cardiovascular Disorders in Africa and Middle-East, 2019 and 2030
10.5.5.1.3. Supergeneric Drugs Market for Respiratory Disorders in Africa and Middle-East, 2019 and 2030
10.5.5.1.4. Supergeneric Drugs Market for Autoimmune Disorders in Africa and Middle-East, 2019 and 2030
10.5.5.1.5. Supergeneric Drugs Market for Metabolic Disorders in Africa and Middle-East, 2019 and 2030
10.5.5.1.6. Supergeneric Drugs Market for Oncological Disorders in Africa and Middle-East, 2019 and 2030
10.5.5.1.7. Supergeneric Drugs Market for Pain Disorders in Africa and Middle-East, 2019 and 2030
10.5.5.1.8. Supergeneric Drugs Market for Other Disorders in Africa and Middle East, 2019 and 2030
10.5.5.2. Supergeneric Drugs Market: Distribution by Route of Administration in Africa and Middle-East
10.5.5.2.1. Supergeneric Drugs Market for Oral Route of Administration in Africa and Middle-East, 2019 and 2030
10.5.5.2.2. Supergeneric Drugs Market for Parenteral Route of Administration in Africa and Middle-East, 2019 and 2030
10.5.5.2.3. Supergeneric Drugs Market for Topical Route of Administration in Africa and Middle-East, 2019 and 2030
10.5.5.2.4. Supergeneric Drugs Market for Intravitreal Route of Administration in Africa and Middle-East, 2019 and 2030
10.5.5.2.5. Supergeneric Drugs Market for Other Routes of Administration in Africa and Middle-East, 2019 and 2030

11 CONCLUSION

12 APPENDIX 1: TABULATED DATA

13 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1 Impact of Number of Drug Manufacturers on Price of Generic Drugs
Figure 3.2 Year-wise Trend of NDA 505(b)(2) Approvals, 2008-2017
Figure 3.3 Distribution of NDA 505(b)(2) Approvals by Submission Classification Code, 2018
Figure 3.4 Advantages Offered by Supergenerics
Figure 3.5 Historical Drug Development Costs
Figure 4.1 Supergenerics: Distribution by Route of Administration
Figure 4.2 Supergenerics: Distribution by Target Indication
Figure 4.3 Supergenerics: Distribution by Target Therapeutic Area
Figure 4.4 Supergenerics: Distribution by Approval Timeline
Figure 4.5 Supergenerics: Distribution by Submission Classification Code
Figure 4.6 Supergenerics: Distribution by Route of Administration, Target Therapeutic Area and Submission Classifiction Code
Figure 4.7 Supergenerics: Most Active players by Number of Approvals
Figure 5.1 Supergeneric Technology Providers: Distribution by Type of Drug Modification
Figure 5.2 Supergeneric Technology Providers: Distribution by Type of Technology
Figure 5.3 Supergeneric Technology Providers: Distribution by Type of Molecules
Figure 5.4 Supergeneric Technology Providers: Distribution by Route of Administration
Figure 5.5 Supergeneric Technology Providers: Distribution by Type of Value Addition
Figure 5.6 Supergeneric Technology Providers: Distribution by Type of Molecule, Route of Administration and Type of Value Additon
Figure 5.7 Supergeneric Technology Providers: Distribution by Year of Establishment
Figure 5.8 Supergeneric Technology Providers: Distribution by Company Size
Figure 5.9. Supergeneric Technology Providers: Distribution by Geography
Figure 5.10 Platform Competitiveness Analysis: Technologies of Companies based in North America (Peer Group I)
Figure 5.11 Platform Competitiveness Analysis: Technologies of Companies based in North America (Peer Group II)
Figure 5.12 Platform Competitiveness Analysis: Technologies of Companies based in Europe
Figure 5.13 Platform Competitiveness Analysis: Technologies of Companies based in Asia-Pacific
Figure 6.1 Ascendia Pharmaceuticals: Technology Portfolio
Figure 6.2 CritiTech: Technology Portfolio
Figure 6.3 Intellipharmaceutics International: Annual Revenues, 2013-2018 (USD Million)
Figure 6.4 Intellipharmaceutics International: Technology Portfolio
Figure 6.5 Kashiv BioSciences: Technology Portfolio
Figure 6.6 LATITUDE Pharmaceuticals: Technology Portfolio
Figure 6.7 Mayne Pharma: Annual Revenues, 2013-2019 (USD Million)
Figure 6.8 Mayne Pharma: Technology Portfolio
Figure 6.9 Rubicon Research: Technology Portfolio
Figure 6.10 Taiwan Liposome Company: Annual Revenues, 2014-H1 2019 (NT$ Million)
Figure 6.11 Taiwan Liposome Company: Technology Portfolio
Figure 6.12 tesa Labtec: Technology Portfolio
Figure 7.1 Austedo®: Development Timeline
Figure 7.2 Revenue Comparison: Xenazine® versus Austedo® (USD Million)
Figure 7.3 Abraxane®: Development Timeline
Figure 7.4 Revenue Comparison: Taxol® versus Abraxane® (USD Million)
Figure 7.5 Annual Revenues: Abraxane® 2012-2018 (USD Million)
Figure 7.6 Avycaz®: Development Timeline
Figure 7.7 Annual Revenues: Avycaz® 2015-2018 (USD Million)
Figure 7.8 Procysbi®: Development Timeline
Figure 7.9 Annual Revenues: Procysbi® 2016-2018 (USD Million)
Figure 7.10 Trokendi XR®: Development Timeline
Figure 7.11 Annual Revenues: Trokendi XR® 2014-2018 (USD Million)
Figure 8.1 Likely Candidates for Supergeneric Development
Figure 9.1 Supergenerics: SWOT Analysis
Figure 9.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 10.1 Supergeneric Drugs: Overall Market Opportunity, 2019-2030 (USD Billion)
Figure 10.2 Supergeneric Drugs Market: Distribution by Therapeutic Area, 2019-2030 (USD Billion) 
Figure 10.3 Supergeneric Drugs Market: Distribution by Route of Administration, 2019-2030 (USD Billion)
Figure 10.4 Supergeneric Drugs Market: Distribution by Geography, 2019-2030 (USD Billion)
Figure 10.5 Supergenerics Drugs Market in North America, 2019-2030 (USD Billion)
Figure 10.6 Supergenerics Drugs Market for CNS Disorders in North America, 2019-2030 (USD Billion)
Figure 10.7 Supergenerics Drugs Market for Cardiovascular Disorders in North America, 2019-2030 (USD Billion)
Figure 10.8 Supergenerics Drugs Market for Respiratory Disorders in North America, 2019-2030 (USD Billion)
Figure 10.9 Supergenerics Drugs Market for Autoimmune Disorders in North America, 2019-2030 (USD Billion)
Figure 10.10 Supergenerics Drugs Market for Metabolic Disorders in North America, 2019-2030 (USD Billion)
Figure 10.11 Supergenerics Drugs Market for Oncological Disorders in North America, 2019-2030 (USD Billion)
Figure 10.12 Supergenerics Drugs Market for Pain Disorders in North America, 2019-2030 (USD Billion)
Figure 10.13 Supergenerics Drugs Market for Other Disorders in North America, 2019-2030 (USD Billion)
Figure 10.14 Supergenerics Drugs Market for Oral Route of Administration in North America, 2019-2030 (USD Billion)
Figure 10.15 Supergenerics Drugs Market for Parenteral Route of Administration in North America, 2019-2030 (USD Billion)
Figure 10.16 Supergenerics Drugs Market for Topical Route of Administration in North America, 2019-2030 (USD Billion)
Figure 10.17 Supergenerics Drugs Market for Intravitreal Route of Administration in North America, 2019-2030 (USD Billion)
Figure 10.18 Supergenerics Drugs Market for Other Routes of Administration in North America, 2019-2030 (USD Billion)
Figure 10.19 Supergenerics Drugs Market in Europe, 2019-2030 (USD Billion)
Figure 10.20 Supergenerics Drugs Market for CNS Disorders in Europe, 2019-2030 (USD Billion)
Figure 10.21 Supergenerics Drugs Market for Cardiovascular Disorders in Europe, 2019-2030 (USD Billion)
Figure 10.22 Supergenerics Drugs Market for Respiratory Disorders in Europe, 2019-2030 (USD Billion)
Figure 10.23 Supergenerics Drugs Market for Autoimmune Disorders in Europe, 2019-2030 (USD Billion)
Figure 10.24 Supergenerics Drugs Market for Metabolic Disorders in Europe, 2019-2030 (USD Billion)
Figure 10.25 Supergenerics Drugs Market for Oncological Disorders in Europe, 2019-2030 (USD Billion)
Figure 10.26 Supergenerics Drugs Market for Pain Disorders in Europe, 2019-2030 (USD Billion)
Figure 10.27 Supergenerics Drugs Market for Others in Europe, 2019-2030 (USD Billion)
Figure 10.28 Supergenerics Drugs Market for Oral Route of Administration in Europe, 2019-2030 (USD Billion)
Figure 10.29 Supergenerics Drugs Market for Parenteral Route of Administration in Europe, 2019-2030 (USD Billion)
Figure 10.30 Supergenerics Drugs Market for Topical Route of Administration in Europe, 2019-2030 (USD Billion)
Figure 10.31 Supergenerics Drugs Market for Intravitreal Route of Administration in Europe, 2019-2030 (USD Billion)
Figure 10.32 Supergenerics Drugs Market for Other Routes of Administration in Europe, 2019-2030 (USD Billion)
Figure 10.33 Supergenerics Drugs Market in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.34 Supergenerics Drugs Market for CNS Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.35 Supergenerics Drugs Market for Cardiovascular Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.36 Supergenerics Drugs Market for Respiratory Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.37 Supergenerics Drugs Market for Autoimmune Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.38 Supergenerics Drugs Market for Metabolic Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.39 Supergenerics Drugs Market for Oncological Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.40 Supergenerics Drugs Market for Pain Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.41 Supergenerics Drugs Market for Others in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.42 Supergenerics Drugs Market for Oral Route of Administration in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.43 Supergenerics Drugs Market for Parenteral Route of Administration in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.44 Supergenerics Drugs Market for Topical Route of Administration in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.45 Supergenerics Drugs Market for Intravitreal Route of Administration in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.46 Supergenerics Drugs Market for Other Routes of Administration in Asia-Pacific, 2019-2030 (USD Billion)
Figure 10.47 Supergenerics Drugs Market in Latin America, 2019-2030 (USD Billion)
Figure 10.48 Supergenerics Drugs Market for CNS Disorders in Latin America, 2019-2030 (USD Billion)
Figure 10.49 Supergenerics Drugs Market for Cardiovascular Disorders in Latin America, 2019-2030 (USD Billion)
Figure 10.50 Supergenerics Drugs Market for Respiratory Disorders in Latin America, 2019-2030 (USD Billion)
Figure 10.51 Supergenerics Drugs Market for Autoimmune Disorders in Latin America, 2019-2030 (USD Billion)
Figure 10.52 Supergenerics Drugs Market for Metabolic Disorders in Latin America, 2019-2030 (USD Billion)
Figure 10.53 Supergenerics Drugs Market for Oncological Disorders in Latin America, 2019-2030 (USD Billion)
Figure 10.54 Supergenerics Drugs Market for Pain Disorders in Latin America, 2019-2030 (USD Billion)
Figure 10.55 Supergenerics Drugs Market for Others in Latin America, 2019-2030 (USD Billion)
Figure 10.56 Supergenerics Drugs Market for Oral Route of Administration in Latin America, 2019-2030 (USD Billion)
Figure 10.57 Supergenerics Drugs Market for Parenteral Route of Administration in Latin America, 2019-2030 (USD Billion)
Figure 10.58 Supergenerics Drugs Market for Topical Route of Administration in Latin America, 2019-2030 (USD Billion)
Figure 10.59 Supergenerics Drugs Market for Intravitreal Route of Administration in Latin America, 2019-2030 (USD Billion)
Figure 10.60 Supergenerics Drugs Market for Other Routes of Administration in Latin America, 2019-2030 (USD Billion)
Figure 10.61 Supergenerics Drugs Market in Africa and Middle-East, 2019-2030 (USD Billion)
Figure 10.62 Supergenerics Drugs Market for CNS Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.63 Supergenerics Drugs Market for Cardiovascular Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.64 Supergenerics Drugs Market for Respiratory Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.65 Supergenerics Drugs Market for Autoimmune Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.66 Supergenerics Drugs Market for Metabolic Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.67 Supergenerics Drugs Market for Oncological Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.68 Supergenerics Drugs Market for Pain Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.69 Supergenerics Drugs Market for Others in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.70 Supergenerics Drugs Market for Oral Route of Administration in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.71 Supergenerics Drugs Market for Parenteral Route of Administration in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.72 Supergenerics Drugs Market for Topical Route of Administration in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.73 Supergenerics Drugs Market for Intravitreal Route of Administration in Africa and Middle East, 2019-2030 (USD Billion)
Figure 10.74 Supergenerics Drugs Market for Other Routes of Administration in Africa and Middle East, 2019-2030 (USD Billion)

List Of Tables

Table 3.1 Different Nomenclatures Used for Value-added Generics
Table 3.2 Comparison of FDA Drug Approval Pathways
Table 3.3 Market Exclusivity Period for Different Submission Classifications
Table 3.4 Comparison of Drug Development Timeline
Table 4.1 Supergenerics: List of FDA Approved Drugs, 2016-2018
Table 4.2 Supergenerics: Additional Details, 2016-2018
Table 5.1 Supergeneric Technology Platforms: List of Technology Providers
Table 5.2 Supergeneric Technology Platforms: Information on Type of Drug Modification, Type of Technology and Type of Molecule Delivered / Formulated
Table 5.3. Supergeneric Technology Platforms: Information on Route of Administration and Type of Value Addition Offered
Table 6.1 List of Profiled Supergeneric Technology Providers
Table 6.2 CritiTech (NanOlogy): Pipeline Overview
Table 6.3 CritiTech (NanOlogy): Recent Developments and Future Outlook
Table 6.4 Crossject: Pipeline Overview
Table 6.5 Crossject: Recent Developments and Future Outlook
Table 6.6 DelSiTech: Pipeline Overview
Table 6.7 DelSiTech: Recent Developments and Future Outlook
Table 6.8 Heron Therapeutics: Recent Developments and Future Outlook
Table 6.9 Intellipharmaceutics International: Recent Developments and Future Outlook
Table 6.10 Kashiv BioSciences: Pipeline Overview
Table 6.11 Mayne Pharma: Recent Developments and Future Outlook
Table 6.12 Neurelis: Pipeline Overview
Table 6.13 Taiwan Liposome Company: Pipeline Overview
Table 6.14 Taiwan Liposome Company: Recent Developments and Future Outlook
Table 7.1 Adverse Events Comparison: Austedo® versus Xenazine®
Table 7.2 Adverse Events Comparison: Abraxane® versus Taxol®
Table 7.3 Adverse Events Comparison: Procysbi® versus Cystagon®
Table 7.4 Adverse Events Comparison: Trokendi XR® versus Topiramate IR®
Table 8.2 Most Likely Candidates for Supergeneric Development
Table 8.3 Likely Candidates for Supergeneric Development
Table 8.4 Less Likely Candidates for Supergeneric Development
Table 8.5 Least Likely Candidates for Supergeneric Development
Table 12.1 Impact of Number of Drug Manufacturers on Price of Generic Drugs
Table 12.2 Year-wise Trend of NDA 505(b)(2) Approvals, 2008-2017
Table 12.3 Distribution of NDA 505(b)(2) Approvals by Submission Classification Code, 2018
Table 12.4 Historical Drug Development Costs
Table 12.5 Supergenerics: Distribution by Route of Administration
Table 12.6 Supergenerics: Distribution by Target Indication
Table 12.7 Supergenerics: Distribution by Target Therapeutic Area
Table 12.8 Supergenerics: Distribution by Approval Timeline
Table 12.9 Supergenerics: Distribution by NDA Submission Classification
Table 12.10 Supergenerics: Most Active players by Number of Approvals
Table 12.11 Supergeneric Technology Providers: Distribution by Type of Drug Modification
Table 12.12 Supergeneric Technology Providers: Distribution by Type of Technology
Table 12.13 Supergeneric Technology Providers: Distribution by Type of Molecules
Table 12.14 Supergeneric Technology Providers: Distribution by Route of Administration
Table 12.15 Supergeneric Technology Providers: Distribution by Type of Value Addition
Table 12.16 Supergeneric Technology Providers: Distribution by Year of Establishment
Table 12.17 Supergeneric Technology Providers: Distribution by Company Size
Table 12.18 Supergeneric Technology Providers: Distribution by Geography
Table 12.19 Intellipharmaceutics International: Annual Revenues, 2013-2018 (USD million)
Table 12.20 Mayne Pharma: Annual Revenues, 2013-2019 (USD Million)
Table 12.21 Taiwan Liposome Company: Annual Revenues, 2014-H1 2019 (NT$ Million)
Table 12.22 Revenue Comparison: Xenazine® versus Austedo® (USD Million)
Table 12.23 Revenue Comparison: Taxol® versus Abraxane® (USD Million)
Table 12.24 Annual Revenues: Abraxane® 2012-2018 (USD Million)
Table 12.25 Annual Revenues: Avycaz® 2015-2018 (USD Million)
Table 12.26 Annual Revenues: Procysbi® 2016-2018 (USD Million)
Table 12.27 Annual Revenues: Trokendi XR® 2014-2018 (USD Million)
Table 12.28 Supergeneric Drugs: Overall Market Opportunity, 2019-2030 (USD Billion)
Table 12.29 Supergeneric Drugs Market: Distribution by Therapeutic Area, 2019-2030 (USD Billion)
Table 12.30 Supergeneric Drugs Market: Distribution by Route of Administration, 2019-2030 (USD Billion)
Table 12.31 Supergeneric Drugs Market: Distribution by Geography, 2019-2030 (USD Billion)
Table 12.32 Supergenerics Drugs Market in North America, 2019-2030 (USD Billion)
Table 12.33 Supergenerics Drugs Market for CNS Disorders in North America, 2019-2030 (USD Billion)
Table 12.34 Supergenerics Drugs Market for Cardiovascular Disorders in North America, 2019-2030 (USD Billion)
Table 12.35 Supergenerics Drugs Market for Respiratory Disorders in North America, 2019-2030 (USD Billion)
Table 12.36 Supergenerics Drugs Market for Autoimmune Disorders in North America, 2019-2030 (USD Billion)
Table 12.37 Supergenerics Drugs Market for Metabolic Disorders in North America, 2019-2030 (USD Billion)
Table 12.38 Supergenerics Drugs Market for Oncological Disorders in North America, 2019-2030 (USD Billion)
Table 12.39 Supergenerics Drugs Market for Pain Disorders in North America, 2019-2030 (USD Billion)
Table 12.40 Supergenerics Drugs Market for Other Disorders in North America, 2019-2030 (USD Billion)
Table 12.41 Supergenerics Drugs Market for Oral Route of Administration in North America, 2019-2030 (USD Billion)
Table 12.42 Supergenerics Drugs Market for Parenteral Route of Administration in North America, 2019-2030 (USD Billion)
Table 12.43 Supergenerics Drugs Market for Topical Route of Administration in North America, 2019-2030 (USD Billion)
Table 12.44 Supergenerics Drugs Market for Intravitreal Route of Administration in North America, 2019-2030 (USD Billion)
Table 12.45 Supergenerics Drugs Market for Other Routes of Administration in North America, 2019-2030 (USD Billion)
Table 12.46 Supergenerics Drugs Market in Europe, 2019-2030 (USD Billion)
Table 12.47 Supergenerics Drugs Market for CNS Disorders in Europe, 2019-2030 (USD Billion)
Table 12.48 Supergenerics Drugs Market for Cardiovascular Disorders in Europe, 2019-2030 (USD Billion)
Table 12.49 Supergenerics Drugs Market for Respiratory Disorders in Europe, 2019-2030 (USD Billion)
Table 12.50 Supergenerics Drugs Market for Autoimmune Disorders in Europe, 2019-2030 (USD Billion)
Table 12.51 Supergenerics Drugs Market for Metabolic Disorders in Europe, 2019-2030 (USD Billion)
Table 12.52 Supergenerics Drugs Market for Oncological Disorders in Europe, 2019-2030 (USD Billion)
Table 12.53 Supergenerics Drugs Market for Pain Disorders in Europe, 2019-2030 (USD Billion)
Table 12.54 Supergenerics Drugs Market for Others in Europe, 2019-2030 (USD Billion)
Table 12.55 Supergenerics Drugs Market for Oral Route of Administration in Europe, 2019-2030 (USD Billion)
Table 12.56 Supergenerics Drugs Market for Parenteral Route of Administration in Europe, 2019-2030 (USD Billion)
Table 12.57 Supergenerics Drugs Market for Topical Route of Administration in Europe, 2019-2030 (USD Billion)
Table 12.58 Supergenerics Drugs Market for Intravitreal Route of Administration in Europe, 2019-2030 (USD Billion)
Table 12.59 Supergenerics Drugs Market for Other Routes of Administration in Europe, 2019-2030 (USD Billion)
Table 12.60 Supergenerics Drugs Market in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.61 Supergenerics Drugs Market for CNS Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.62 Supergenerics Drugs Market for Cardiovascular Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.63 Supergenerics Drugs Market for Respiratory Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.64 Supergenerics Drugs Market for Autoimmune Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.65 Supergenerics Drugs Market for Metabolic Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.66 Supergenerics Drugs Market for Oncological Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.67 Supergenerics Drugs Market for Pain Disorders in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.68 Supergenerics Drugs Market for Others in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.69 Supergenerics Drugs Market for Oral Route of Administration in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.70 Supergenerics Drugs Market for Parenteral Route of Administration in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.71 Supergenerics Drugs Market for Topical Route of Administration in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.72 Supergenerics Drugs Market for Intravitreal Route of Administration in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.73 Supergenerics Drugs Market for Other Routes of Administration in Asia-Pacific, 2019-2030 (USD Billion)
Table 12.74 Supergenerics Drugs Market in Latin America, 2019-2030 (USD Billion)
Table 12.75 Supergenerics Drugs Market for CNS Disorders in Latin America, 2019-2030 (USD Billion)
Table 12.76 Supergenerics Drugs Market for Cardiovascular Disorders in Latin America, 2019-2030 (USD Billion)
Table 12.77 Supergenerics Drugs Market for Respiratory Disorders in Latin America, 2019-2030 (USD Billion)
Table 12.78 Supergenerics Drugs Market for Autoimmune Disorders in Latin America, 2019-2030 (USD Billion)
Table 12.79 Supergenerics Drugs Market for Metabolic Disorders in Latin America, 2019-2030 (USD Billion)
Table 12.80 Supergenerics Drugs Market for Oncological Disorders in Latin America, 2019-2030 (USD Billion)
Table 12.81 Supergenerics Drugs Market for Pain Disorders in Latin America, 2019-2030 (USD Billion)
Table 12.82 Supergenerics Drugs Market for Others in Latin America, 2019-2030 (USD Billion)
Table 12.83 Supergenerics Drugs Market for Oral Route of Administration in Latin America, 2019-2030 (USD Billion)
Table 12.84 Supergenerics Drugs Market for Parenteral Route of Administration in Latin America, 2019-2030 (USD Billion)
Table 12.85 Supergenerics Drugs Market for Topical Route of Administration in Latin America, 2019-2030 (USD Billion)
Table 12.86 Supergenerics Drugs Market for Intravitreal Route of Administration in Latin America, 2019-2030 (USD Billion)
Table 12.87 Supergenerics Drugs Market for Other Routes of Administration in Latin America, 2019-2030 (USD Billion)
Table 12.88 Supergenerics Drugs Market in Africa and Middle-East, 2019-2030 (USD Billion)
Table 12.89 Supergenerics Drugs Market for CNS Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.90 Supergenerics Drugs Market for Cardiovascular Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.91 Supergenerics Drugs Market for Respiratory Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.92 Supergenerics Drugs Market for Autoimmune Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.93 Supergenerics Drugs Market for Metabolic Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.94 Supergenerics Drugs Market for Oncological Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.95 Supergenerics Drugs Market for Pain Disorders in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.96 Supergenerics Drugs Market for Others in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.97 Supergenerics Drugs Market for Oral Route of Administration in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.98 Supergenerics Drugs Market for Parenteral Route of Administration in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.99 Supergenerics Drugs Market for Topical Route of Administration in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.100 Supergenerics Drugs Market for Intravitreal Route of Administration in Africa and Middle East, 2019-2030 (USD Billion)
Table 12.101 Supergenerics Drugs Market for Other Routes of Administration in Africa and Middle East, 2019-2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 3M
  2. 3SBio
  3. Abon Pharmaceuticals
  4. Abraxis BioScience (a subsidiary of Celgene)
  5. Accord Healthcare 
  6. AcelRx Pharmaceuticals
  7. Aclaris Therapeutics
  8. Acorda Therapeutics
  9. Acrotech Biopharma
  10. ACS Dobfar
  11. Actavis (a subsidiary of Teva Pharmaceutical)
  12. Adamis Pharmaceuticals 
  13. ADDMEDICA
  14. ADIENNE
  15. Aegis Therapeutics 
  16. Ailex Pharmaceuticals
  17. Akorn 
  18. Alcon
  19. Alembic Pharmaceuticals
  20. Allergan
  21. ALRISE Biosystems
  22. Altaire Pharmaceuticals
  23. Altus Formulation
  24. Alyvant
  25. American Regent
  26. Amerigen Pharmaceuticals
  27. Amneal Pharmaceuticals
  28. ANI Pharmaceuticals
  29. Antares Pharma 
  30. Apotex
  31. Aprecia Pharmaceuticals
  32. Armstrong Pharmaceuticals
  33. Ascendia Pharmaceuticals
  34. Ascendis Pharma
  35. Assertio Therapeutics
  36. AstraZeneca
  37. Aurobindo Pharma 
  38. Avadel Pharmaceuticals
  39. Avanir Pharmaceuticals
  40. Avedro 
  41. Avion Pharmaceuticals
  42. B. Braun
  43. Bausch & Lomb 
  44. Baxter
  45. Bayer
  46. BDD 
  47. Belcher Pharmaceuticals
  48. Bharat Serums and Vaccines
  49. BioDelivery Sciences International
  50. Birdie Pharmaceuticals
  51. Bracco
  52. Braeburn
  53. Bristol-Myers Squibb
  54. BWX Technologies
  55. Celator Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals)
  56. Celgene
  57. Cellix Bio
  58. Celltrion Healthcare
  59. Chiesi Farmaceutici 
  60. Cintex
  61. Cipla
  62. CMP Pharma
  63. Cocoon Biotech
  64. Coeptis Pharmaceuticals
  65. Covis Pharma 
  66. Cristal Therapeutics
  67. CritiTech
  68. Crossject
  69. C-Tri
  70. Cycle Pharmaceuticals
  71. Dauntless Pharmaceuticals 
  72. DelNova Healthcare
  73. DelSiTech
  74. Desitin Pharma
  75. Dexcel Pharma
  76. DFB Pharmaceuticals 
  77. DisperSol Technologies
  78. Dr. Reddy's Laboratories
  79. Druggability Technologies
  80. EASYWELL BIOMEDICALS
  81. ECI Pharmaceuticals
  82. Edenbridge Pharmaceuticals
  83. ELPEN
  84. Emmaus Life Sciences
  85. Encore Dermatology
  86. EPI Health
  87. epinamics
  88. Eurohealth International
  89. Exela Pharma Sciences
  90. EyePoint Pharmaceuticals
  91. Eyevance Pharmaceuticals
  92. Ferring Pharmaceuticals 
  93. Flexion Therapeutics
  94. Foresee Pharmaceuticals
  95. Fresenius Kabi
  96. Galderma 
  97. General Atlantic
  98. Genus Lifesciences
  99. Gland Pharma 
  100. GlaxoSmithKline
  101. Glenmark Pharmaceuticals 
  102. GP Pharm
  103. Handa Pharmaceuticals
  104. Hanmi Pharmaceutical
  105. HANSAmed
  106. HealthCare Royalty Partners 
  107. Heron Therapeutics
  108. Hetero
  109. Horizon Therapeutics
  110. Hospira 
  111. HQ Speciality Pharma
  112. Hyundai Bioscience
  113. IBSA Institut Biochimique
  114. iCeutica
  115. Impax Laboratories
  116. Impel NeuroPharma
  117. Indivior 
  118. InfoRLife
  119. Ingenus Pharmaceuticals
  120. Insmed 
  121. INSYS Therapeutics
  122. Intec Pharma
  123. Integral BioSystems
  124. IntelGenx
  125. Intellipharmaceutics International
  126. Intersect ENT
  127. Inventia Healthcare
  128. Ironshore Pharmaceuticals
  129. Italfarmaco
  130. Jiangsu Hengrui Medicine
  131. Jixi Biotechnology 
  132. Johnson & Johnson 
  133. Jubilant DraxImage 
  134. Kala Pharmaceuticals 
  135. Kaleo
  136. Kashiv BioSciences
  137. KC Pharmaceuticals 
  138. KemPharm
  139. Keystone Nano
  140. KVK Tech
  141. Larken Laboratories
  142. LATITUDE Pharmaceuticals
  143. leon-nanodrugs
  144. LipoSeuticals
  145. Liquidia Technologies
  146. Lundbeck
  147. Lupin
  148. Macleods Pharmaceuticals
  149. Mallinckrodt Pharmaceuticals
  150. Mayne Pharma
  151. Medesis Pharma
  152. MedinCell
  153. Medline Industries
  154. Merck
  155. Meridian Medical Technologies 
  156. Micelle BioPharma
  157. Mikart
  158. Mipharm
  159. Mithra Pharmaceuticals
  160. MSN Laboratories
  161. Mylan
  162. Nanocopoeia
  163. NanoVelos
  164. Natco Pharma
  165. NAVINTA
  166. Neos Therapeutics
  167. Nesher Pharmaceuticals
  168. Neurelis
  169. Nexus Pharmaceuticals
  170. Northstar Medical Radioisotopes
  171. Norton (Waterford)
  172. Nostrum Laboratories
  173. NOVADAQ Technologies (a subsidiary of Stryker)
  174. Novatech
  175. Novel Laboratories
  176. Novocol Healthcare
  177. NX Development
  178. Ocular Therapeutix
  179. Opiant Pharmaceuticals
  180. Optinose
  181. Osmotica Pharmaceuticals
  182. Paddock Laboratories 
  183. Par Pharmaceutical
  184. Par Sterile Products (a subsidiary of Par Pharmaceutical)
  185. Pearl Therapeutics
  186. Perrigo
  187. Pfizer 
  188. Pharmadax
  189. PLx Pharma
  190. Praxair
  191. ProSolus
  192. Provepharm Life Solutions
  193. Raptor Pharmaceuticals
  194. Recordati
  195. Rempex Pharmaceuticals
  196. Rising Pharmaceuticals
  197. Rosemont Pharmaceuticals
  198. Roxane Laboratories (a subsidiary of Hikma Pharmaceuticals)
  199. Rubicon Research
  200. RxMP Therapeutics
  201. Sagent Pharmaceuticals
  202. Salvat 
  203. Sandoz 
  204. SCILEX Pharmaceuticals 
  205. SGN Nanopharma
  206. Shanghai Hengrui Pharmaceutical
  207. Silvergate Pharmaceuticals
  208. Solani Therapeutics 
  209. Sol-Gel Technologies
  210. Spear Pharmaceuticals 
  211. St. Renatus
  212. Sun Pharmaceutical
  213. Sunny Pharmtech
  214. Sunovion Pharmaceuticals
  215. Supernus Pharmaceuticals 
  216. Taiwan Liposome Company
  217. Taro Pharmaceuticals
  218. Teligent
  219. TerSera Therapeutics 
  220. tesa Labtec
  221. Teva Pharmaceutical
  222. TherapeuticsMD 
  223. Tiger Pharmaceuticals
  224. Titan Pharmaceuticals 
  225. Tolmar
  226. Torrent Pharmaceuticals
  227. Tris Pharma
  228. Upsher-Smith Laboratories
  229. US Biotest 
  230. Valeant Pharmaceuticals 
  231. West-Ward Pharmaceuticals
  232. Xellia
  233. X-GEN Pharmaceuticals
  234. Zydus Cadila

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.